Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BYSI | US
-0.10
-4.02%
Healthcare
Biotechnology
31/03/2024
16/10/2024
2.39
2.32
2.40
2.27
BeyondSpring Inc. a clinical stage biopharmaceutical company together with its subsidiaries focuses on the development of cancer therapies. The company's lead asset is the Plinabulin a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents including nivolumab a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York New York.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
71.1%1 month
65.1%3 months
62.2%6 months
82.1%-
10.54
5.38
-0.15
0.16
0.05
47.80
-
-16.71M
96.32M
96.32M
-
-742.20
-
14.30
-310.48
79.33
8.74
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.38
Range1M
0.57
Range3M
0.91
Rel. volume
0.65
Price X volume
36.48K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Prelude Therapeutics Incorporated | PRLD | Biotechnology | 1.94 | 105.93M | 1.57% | n/a | 9.99% |
Regulus Therapeutics Inc | RGLS | Biotechnology | 1.59 | 104.09M | 6.00% | n/a | 1.45% |
INmune Bio Inc | INMB | Biotechnology | 5.21 | 103.32M | 7.87% | n/a | 14.65% |
Coherus BioSciences Inc | CHRS | Biotechnology | 0.8866 | 102.14M | -2.58% | n/a | -354.71% |
Agenus Inc | AGEN | Biotechnology | 4.68 | 100.96M | 0.43% | n/a | -170.56% |
AVTX | AVTX | Biotechnology | 10.29 | 99.81M | 6.19% | n/a | -80.47% |
Marinus Pharmaceuticals Inc | MRNS | Biotechnology | 1.8 | 99.15M | 3.45% | n/a | -202.54% |
Oramed Pharmaceuticals Inc | ORMP | Biotechnology | 2.43 | 99.07M | 3.40% | 4.67 | 0.00% |
Oncolytics Biotech Inc. (USA) | ONCY | Biotechnology | 1.25 | 96.07M | 0.81% | n/a | 0.00% |
BioAtla Inc. | BCAB | Biotechnology | 1.96 | 94.74M | 0.51% | n/a | 5.30% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.49 | 93.31M | 1.12% | 5.27 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.34 | 89.79M | -0.14% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.5 | 19.04M | 4.17% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.02 | 18.42M | 2.01% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.6542 | 9.49M | -5.19% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2051 | 3.68M | -6.82% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.09 | 2.84M | -0.91% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -0.99% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.42 | 0 | 2.63% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.21 | 0 | 3.19% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.05 | 0.53 | Cheaper |
Ent. to Revenue | 47.80 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 5.38 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 62.23 | 72.92 | Par |
Debt to Equity | -0.15 | -1.24 | Expensive |
Debt to Assets | 0.16 | 0.25 | Cheaper |
Market Cap | 96.32M | 3.78B | Emerging |